Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | EEF2K | O00418 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701951 | 0.88 | CA12 (0.71) | CA1CA2KMT2AHTTLMNA | |
| SCHEMBL7834044 | 0.86 | HTR6 (0.72) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL23057261 | 0.85 | IDO1 (0.72) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL28271812 | 0.85 | HTR6 (1.00) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL31681311 | 0.85 | CA12 (0.66) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL259382 | 0.85 | CA12 (0.66) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL31681359 | 0.84 | LMNA (0.58) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL9763115 | 0.84 | HTR6 (0.79) | HTR6CA1CA2KMT2AHTT | |
| SCHEMBL13875341 | 0.84 | L3MBTL1 (0.67) | CA1CA2KMT2AHTTLMNA | |
| SCHEMBL28560165 | 0.84 | CA12 (0.65) | CA1CA2KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | HTR6 1222/4885CA1 1931/4885CA2 2548/4885 |
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | MDM2, TP53, RECQL | HTR6 2376/4885CA1 4342/4885CA2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.